Hyperthermic pressurized intraperitoneal aerosol drug delivery system in a large animal model : a feasibility and safety study
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND: We developed a novel drug delivery system called hyperthermic pressurized intraperitoneal aerosol chemotherapy (HPIPAC) that hybridized Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC). The present study aims to assess the feasibility and safety of HPIPAC system in a large animal survival model.
METHODS: Eleven pigs (eight non-survival models and three survival models) were used in the experiment. The heat module in the HPIPAC controller circulates hyperthermic CO2 in a closed-loop circuit and creates gas-based dry intraperitoneal hyperthermia. Three 12 mm trocars were placed on the abdomen. The afferent CO2 tube wound with heat generating coil was inserted into a trocar, and the efferent tube was inserted into another trocar. Heated CO2 was insufflated and circulated in a closed circuit until the intra-abdominal and peritoneal surface temperature reached 42 °C. 100 ml of 5% dextrose in water was nebulized for 5 min and the closed-loop circulation was resumed for 60 min at 42 °C. Tissue biopsies were taken from several sites from the pigs in the survival model.
RESULTS: The average change in core temperature of the pigs was 2.5 ± 0.08 °C. All three pigs displayed no signs of distress, and their vital signs remained stable, with no changes in their diet. In autopsy, inflammatory and fibrotic responses at the biopsy sites were observed without serious pathologic findings.
CONCLUSIONS: We successfully proved the feasibility and safety of our novel HPIPAC system in an in-vivo swine survival model.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Surgical endoscopy - 38(2024), 4 vom: 29. Apr., Seite 2062-2069 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Min, Sa-Hong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
142M471B3J |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00464-024-10702-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369194500 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369194500 | ||
| 003 | DE-627 | ||
| 005 | 20240401232712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00464-024-10702-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM369194500 | ||
| 035 | |a (NLM)38429574 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Min, Sa-Hong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperthermic pressurized intraperitoneal aerosol drug delivery system in a large animal model |b a feasibility and safety study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a BACKGROUND: We developed a novel drug delivery system called hyperthermic pressurized intraperitoneal aerosol chemotherapy (HPIPAC) that hybridized Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC). The present study aims to assess the feasibility and safety of HPIPAC system in a large animal survival model | ||
| 520 | |a METHODS: Eleven pigs (eight non-survival models and three survival models) were used in the experiment. The heat module in the HPIPAC controller circulates hyperthermic CO2 in a closed-loop circuit and creates gas-based dry intraperitoneal hyperthermia. Three 12 mm trocars were placed on the abdomen. The afferent CO2 tube wound with heat generating coil was inserted into a trocar, and the efferent tube was inserted into another trocar. Heated CO2 was insufflated and circulated in a closed circuit until the intra-abdominal and peritoneal surface temperature reached 42 °C. 100 ml of 5% dextrose in water was nebulized for 5 min and the closed-loop circulation was resumed for 60 min at 42 °C. Tissue biopsies were taken from several sites from the pigs in the survival model | ||
| 520 | |a RESULTS: The average change in core temperature of the pigs was 2.5 ± 0.08 °C. All three pigs displayed no signs of distress, and their vital signs remained stable, with no changes in their diet. In autopsy, inflammatory and fibrotic responses at the biopsy sites were observed without serious pathologic findings | ||
| 520 | |a CONCLUSIONS: We successfully proved the feasibility and safety of our novel HPIPAC system in an in-vivo swine survival model | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hyperthermic intraperitoneal chemotherapy | |
| 650 | 4 | |a Large animal model | |
| 650 | 4 | |a Peritoneal carcinomatosis | |
| 650 | 4 | |a Pressurized intraperitoneal aerosol chemotherapy | |
| 650 | 7 | |a Carbon Dioxide |2 NLM | |
| 650 | 7 | |a 142M471B3J |2 NLM | |
| 650 | 7 | |a Aerosols |2 NLM | |
| 700 | 1 | |a Yoo, Mira |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Duyeong |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Eunju |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, So Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sangjun |e verfasserin |4 aut | |
| 700 | 1 | |a Won, Yongjoon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Young Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Sang-Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyung-Ho |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgical endoscopy |d 1996 |g 38(2024), 4 vom: 29. Apr., Seite 2062-2069 |w (DE-627)NLM012660159 |x 1432-2218 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:4 |g day:29 |g month:04 |g pages:2062-2069 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00464-024-10702-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 4 |b 29 |c 04 |h 2062-2069 | ||